Is lipoprotein(a) an LDL-like particle bound to apolipoprotein(a) that raises cardiovascular risk independently of LDL cholesterol?

Lipoprotein(a) [Lp(a)] is a specialized lipoprotein that significantly contributes to cardiovascular risk through mechanisms distinct from traditional cholesterol markers. For an individual in their 70s, understanding the independence of this marker is crucial, as it identifies residual risk that may persist even if LDL cholesterol (LDL-C) levels are well-controlled.

Molecular structure and assembly

• Structural Composition: Lp(a) is formed by a low-density lipoprotein (LDL) particle covalently linked to a unique glycoprotein called apolipoprotein(a) [apo(a)]. This assembly occurs via a disulfide bridge between the apolipoprotein B-100 (apoB-100) on the LDL particle and the apo(a) molecule.
• Assembly Mechanism: The process involves a specific two-step interaction. Initially, noncovalent docking occurs between the lysine-binding sites on apo(a) and the amino-terminal region of apoB-100. This is followed by the formation of a permanent covalent bond, primarily between Cysteine 4326 on apoB-100 and Cysteine 4057 on apo(a).

Clinical risk and independence

• Independent Risk Factor: Large-scale prospective studies and Mendelian randomization trials confirm that Lp(a) is a causal, independent risk factor for atherosclerotic cardiovascular disease (ASCVD). In multivariable analyses, the association remains significant after adjusting for LDL-C, with hazard ratios for cardiovascular events typically ranging from 0.75 to 3.7 depending on the population.
• Mechanistic Pathways: The risk is independent because apo(a) introduces pathogenic features that LDL particles lack. These include a high affinity for oxidized phospholipids, which drive arterial wall inflammation, and a structural homology to plasminogen, which allows Lp(a) to inhibit fibrinolysis and promote a pro-thrombotic state.

Considerations for older adults

• Continued Relevance: Evidence from cohorts aged 70 and older indicates that Lp(a) remains a potent predictor of coronary artery disease. In statin-naïve elderly populations, research shows an odds ratio of approximately 1.012 per mg/dL increase in Lp(a) after adjusting for cumulative LDL-C exposure. While relative risk may slightly attenuate with age, the absolute risk remains high due to the higher baseline prevalence of vascular disease in this age group.

Bottom line

Lp(a) is an LDL-like particle bound to apolipoprotein(a) that drives cardiovascular risk through inflammation and thrombosis pathways independent of LDL-C. It remains a critical marker for assessing residual risk in older adults, even when traditional lipid targets are achieved.